Skip to main content

Biologic/Novel Rx

Podcast microphone headphones
Day 1 (part one): ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Day 1 (part two): ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Day 4: ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Panel Presentation: Psoriatic Arthritis

Drs. Eric Ruderman, Alexis Ogdie, Jessica Walsh, and Jose Scher discuss the giselkumab trials, where IL-23 inhibitors fit in practice, ixekizumab withdrawal, and more that presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Panel Presentation: Spondyloarthritis

Drs. Jack Cush, Christopher Ritchlin, Sophia Ramiro, Lianne Gensler, and Jessica Walsh discuss interesting new trials and data presented in ankylosing spondylitis and spondyloarthritis at the 2019 ACR/ARP annual meeting in Atlanta.  

Panel Presentation: Gout

Drs. Jack Cush, Nicola Dalbreth, Ken Saag and Robert Keenan discuss several gout presentations, including tart cherry, safety and efficacy of therapies, quality of life issues and more at the 2019 ACR/ARP annual meeting in Atlanta. 

RT @synovialjoints: Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and a…

Dr. Antoni Chan synovialjoints

6 months 2 weeks ago

Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and abstract #2729 is promising as treatment options for patients #ACR19 @RheumNow

RT @synovialjoints: The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected…

Dr. Antoni Chan synovialjoints

6 months 2 weeks ago

The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected safety findings. IXE superior to PBO for improving signs, symptoms, and inflammation on MRI in pts with nr-axSpA abstract #2729 #ACR19 @RheumNow

RT @synovialjoints: PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs…

Dr. Antoni Chan synovialjoints

6 months 2 weeks ago

PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs and symptoms of nr-axSpA through Wk 16. The safety profile of SEC was consistent with the established safety profile across indications #L2 #ACR19 @RheumNow

Romosozumab and Patients with Chronic Kidney Disease: Dr. Arthur Lau

Dr. Lau discusses abstract #2730 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

New Treatments for Axial Spondyloarthritis: Dr. Antoni Chan

Dr. Chan discusses several studies on spondyloarthritis presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Ixekizimab Withdrawal in PSA: Dr. Eric Ruderman

Dr. Ruderman highlights abstract #1532 at the 2019 ACR/ARP annual meeting in Atlanta.

TULIP Trials in Lupus: Dr. Mike Putman

Dr. Putman discusses abstracts # L17 and 1763 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Comparison of Ixekizumab and Adalimumab in PsA: Dr. Olga Petryna

Dr. Petryna discusses abstract #L20 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Overview of Several Gout Studies: Dr. Philip Robinson

Dr. Robinson highlights a number of gout-related abstracts, including #1236, #1217, #1218, #1235, at the ACR/ARP annual meeting in Atlanta. 

Subcutaneous Biosimilar: Dr. Jonathan Kay

Dr. Kay highlights abstract #548 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

RT @Janetbirdope: Tofacitinib works in Polyarticular JIA. Maybe new hope for kids with JIA and benefits of oral medication #ACR #ACR19 #JIA…

Janet Pope Janetbirdope

6 months 2 weeks ago

Tofacitinib works in Polyarticular JIA. Maybe new hope for kids with JIA and benefits of oral medication #ACR #ACR19 #JIA @RheumNow L23.

RT @Janetbirdope: 1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how th…

Janet Pope Janetbirdope

6 months 2 weeks ago

1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how they get reimbursement #ACR #ACR19 #psoriaticarthritis @RheumNow abstract 1481

RT @Janetbirdope: Remission ever or sustained in RA is same on triple DMARDs Therapy bs biological Rx. From Swedish register. ?channeling b…

Janet Pope Janetbirdope

6 months 2 weeks ago

Remission ever or sustained in RA is same on triple DMARDs Therapy bs biological Rx. From Swedish register. ?channeling bias ?differential access? Either way this supports triple therapy use as impt in RA #ACR #ACR19 @RheumNow Abstract 2908 https://t.co/T8fRPr5a2A

×